{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:24:16Z","timestamp":1787066656152,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We present the results of a phase 1 study that evaluated the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary disease response to cusatuzumab, a novel anti\u2010CD70 monoclonal antibody, in combination with azacitidine, in newly diagnosed acute myeloid leukemia Japanese participants who were not candidates for intensive treatment. In this multicenter, single\u2010arm study, six participants were enrolled and treated. Only in cycle 1, participants received cusatuzumab monotherapy on day 14. Subsequently, cusatuzumab was administered intravenously on days 3 and 17 at 20\u2009mg\/kg in combination with azacitidine (75\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) on days 1\u20107 of each 28\u2010day cycle. All six participants had at least one treatment\u2010emergent adverse event, and the most common treatment\u2010emergent adverse events (all grades) were leukopenia (four participants [66.7%]) and constipation (three participants [50.0%]). No dose\u2010limiting toxicity was observed during the study period. The combination of cusatuzumab and azacitidine is generally well tolerated in Japanese participants, and further exploration of this combination is warranted.\n                  <\/jats:p>","DOI":"10.1111\/cas.15663","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T04:32:32Z","timestamp":1668659552000},"page":"1037-1044","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment"],"prefix":"10.1111","volume":"114","author":[{"given":"Takayuki","family":"Ikezoe","sequence":"first","affiliation":[{"name":"Department of Hematology Fukushima Medical University  Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[{"name":"Department of Hematology NTT Medical Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Aida","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Hatayama","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Shirahase","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-812X","authenticated-orcid":false,"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology University of Fukui  Fukui Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Ministry of Health Labour and Welfare Patient Survey 2017. Accessed June 23 2022.https:\/\/www.e\u2010stat.go.jp\/statsearch\/files?page=1&layout=datalist&toukei=00450022&tstat=000001031167&cycle=7&tclass1=000001124800&tclass2=000001124803&stat_infid=000031790842"},{"key":"e_1_2_11_3_1","unstructured":"Japan Society of Hematology guideline for tumors of hematopoietic and lymphoid tissues 2018. Accessed June 23 2022.http:\/\/www.jshem.or.jp\/gui\u2010hemali\/table.html"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_11_5_1","first-page":"125","article-title":"Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia","volume":"4","author":"Saliba AN","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.02.005"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.27398"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2005.04.004"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.12.3.341"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0910-8"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2791"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20152008"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26190"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0613"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15663","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.15663","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T05:58:10Z","timestamp":1692338290000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.15663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/cas.15663"],"URL":"https:\/\/doi.org\/10.1111\/cas.15663","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"2022-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}